January 2017 in “Faculty of 1000 Research Ltd” Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.
40 citations
,
September 2017 in “F1000Research” In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.
November 2025 in “Faculty of 1000 Research Ltd” In this study of 36 women with chronic telogen effluvium, once daily oral minoxidil significantly reduced hair shedding over 12 months, though some participants experienced facial hypertrichosis and other mild side effects. The authors concluded that placebo-controlled studies are needed to confirm these results.
3 citations
,
March 2022 in “Archives of Dermatological Research” This study reported that oral minoxidil was associated with clinical improvement in androgenetic alopecia and telogen effluvium, showing better outcomes compared to controls.
September 2024 in “Journal of Skin and Stem Cell” In this study, a combination treatment of microinfusion (MMP®) and topical minoxidil showed a modest increase in hair density in a 28-year-old woman with chronic telogen effluvium, particularly in the parieto-vertex region, suggesting potential benefits but underscoring the need for larger trials to confirm efficacy.